•  
  •  
  •  
  •  

2026-01-03 09:41:02

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Dixon Technologies India Ltd's subsidiaries granted approval by MeitY under ECMS
  • Adani Enterprises launches its 3rd public issue of NCDs of ₹1,000 crore, offering up to 8.90% per annum
  • KPI Green Energy Ltd's 92.15 MWp IPP Hybrid Power Project awarded by GUVNL begins supplying power ahead of schedule
  • Karthikeyan Manickam is the New Chairman of ESAF Small Finance Bank
  • Nifty Surges Nearly 200 Points to Close at All-Time High on Broad-Based Buying

Keywords Selected:  ANDAApproval

Stock Report

  • Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
  • Caplin Steriles Ltd receives USFDA final approval for ANDA Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
  • Granules India Limited receives ANDA approval for Glycopyrrolate Oral Solution
  • Unichem Laboratories Ltd receives ANDA approval for Doxazosin Tablets
  • Granules India Ltd received ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules
  • Granules India Ltd received ANDA Approval for Losartan and Hydrochlorothiazide Tablets
  • Granules India Ltd received US FDA approval for the ANDA filed for Metoprolol Succinate ER Tablets
  • Lupin Launches Thiamine Hydrochloride Injection USP in the United States
  • NATCO receives final approval for Tipiracil Hydrochloride and Trifluridine for the US market
  • Lupin receives approval from U.S. FDA for Obeticholic Acid Tablets
  • Unichem Laboratories Ltd receives ANDA approval for Ranolazine Extended-Release Tablets
  • Granules India Ltd received ANDA Approval for Losartan Potassium Tablets
  • Jubilant's Radiopharma business receives NDA approval for Technetium Mertiatide Injection
  • Lupin receives approval from U.S. FDA for Brivaracetam Tablets
  • Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg
  • JB Chemicals & Pharmaceuticals Ltd receives ANDA approval for Venlafaxine Hydrochloride Extended-Release Tablets from USFDA
  • Unichem Laboratories receives ANDA approval for Extended Phenytoin Sodium Capsules
  • Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets USP, 25 mg and 50 mg
  • Granules India Ltd received ANDA Approval for Guaifenesin and Pseudoephedrine Hydrochloride Extended-Release Tablets
  • Unichem Laboratories receives ANDA approval from USFDA for Carbamazepine Tablets USP
  • Lupin receives approval from U.S. FDA for Rufinamide Tablets USP
  • Unichem Laboratories receives ANDA Approval for Quetiapine Extended-Release Tablets
  • Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP
  • Alembic Pharmaceuticals receives USFDA final approvl for Arformoterol Tartrate Inhalation Solution

Latest Post

  • Dixon Technologies India Ltd's subsidiaries granted approval by MeitY under ECMS
  • Adani Enterprises launches its 3rd public issue of NCDs of ₹1,000 crore, offering up to 8.90% per annum
  • KPI Green Energy Ltd's 92.15 MWp IPP Hybrid Power Project awarded by GUVNL begins supplying power ahead of schedule
  • Karthikeyan Manickam is the New Chairman of ESAF Small Finance Bank
  • Nifty Surges Nearly 200 Points to Close at All-Time High on Broad-Based Buying


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025